In a filing, Vertex Pharmaceuticals, Inc revealed its Officer ALTSHULER DAVID acquired Company’s shares for reported $7178.0 on Nov 15 ’24. In the deal valued at $478.56 per share,15 shares were bought.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, WAGNER CHARLES F JR sold 3,000 shares, generating $1,554,810 in total proceeds. Upon selling the shares at $518.27, the EVP & Chief Financial Officer now owns 44,137 shares.
Before that, Kewalramani Reshma sold 15,198 shares. Vertex Pharmaceuticals, Inc shares valued at $7,826,970 were divested by the CEO & President at a price of $515.00 per share. As a result of the transaction, Kewalramani Reshma now holds 75,772 shares, worth roughly $35.29 million.
Citigroup initiated its Vertex Pharmaceuticals, Inc [VRTX] rating to a Buy in a research note published on November 14, 2024; the price target was $575. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in mid October with a ‘”a Sector perform”‘ rating. Barclays revised its rating on August 05, 2024. It rated VRTX as “an Equal weight” which previously was an “an Overweight”.
Price Performance Review of VRTX
On Friday, Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] saw its stock fall -3.77% to $465.70. Over the last five days, the stock has lost -9.88%. Vertex Pharmaceuticals, Inc shares have risen nearly 14.45% since the year began. Nevertheless, the stocks have risen 33.31% over the past one year. While a 52-week high of $519.88 was reached on 11/08/24, a 52-week low of $341.90 was recorded on 04/18/24. SMA at 50 days reached $476.39, while 200 days put it at $453.57.
Levels Of Support And Resistance For VRTX Stock
The 24-hour chart illustrates a support level at 455.89, which if violated will result in even more drops to 446.08. On the upside, there is a resistance level at 477.72. A further resistance level may holdings at 489.75. The Relative Strength Index (RSI) on the 14-day chart is 42.21, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -5.29, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 87.70%. Stochastics %K at 34.82% indicates the stock is a holding.
How much short interest is there in Vertex Pharmaceuticals, Inc?
A steep rise in short interest was recorded in Vertex Pharmaceuticals, Inc stocks on 2024-10-31, growing by 0.43 million shares to a total of 4.5 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 4.08 million shares. There was a rise of 9.51%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 27, 2024 when Redburn Atlantic began covering the stock and recommended ‘”a Buy”‘ rating along with a $545 price target.
